# Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain

> **NCT00365820** · PHASE2,PHASE3 · TERMINATED · sponsor: **Novartis** · enrollment: 670 (—)

## Conditions studied

- Constipation

## Interventions

- **DRUG:** Tegaserod

## Key facts

- **NCT ID:** NCT00365820
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 670 (—)
- **Why stopped:** This study was terminated early as a result of regulatory action suspending tegaserod use in 2007
- **Last updated:** 2012-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00365820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00365820, "Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00365820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*